$FMTX News

Last published 3y ago

3y agoFMTXApproval of Rezlidhia, Nda #215814 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 12/01/2022; Drug Name: Rezlidhia, Nda #215814; Active Ingredients: OLUTASIDENIB; Company: Forma Therapeutics, Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 215814
4y agoFMTXSickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the DiseaseBusiness WireThe "Believe it!" Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (NASDAQ:FMTX
4y agoFMTXNovo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disordersBusiness WireNovo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value
4y agoFMTXForma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness WireAnnounced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rig
4y agoFMTXForma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced that it will release second quarter 2022 f
4y agoFMTXForma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín
4y agoFMTXForma Therapeutics Announces Appointment of New Executive Team MembersBusiness WireAgustín Melián, M.D. to be named Executive Vice President, Head of Research and Development and Linea Aspesi to be named Senior Vice President, Chief Human Resources Officer Appointments position Forma for the next phase of growth in late-stage glo
4y agoFMTXForma Therapeutics Announces Presentations at Upcoming Hematology ConferencesBusiness WireUpdated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent (TD) SCD or non-TD/TD thalassemia Forma T
4y agoFMTXForma Therapeutics to Present at the Jefferies Healthcare ConferenceBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will participate in the Jefferies Health
4y agoFMTXForma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) DayBusiness WireExpanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 trial of FT-7051 in mCRPC proceeding with predicted efficacious dose
4y agoFMTXForma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness WireClinical programs advancing in rare hematologic diseases and cancers May 26 R&D Day to focus on research pipeline strategy and expanded development programs Cash balance of $441.3 million positions company with runway through the third quarter of
4y agoFMTXForma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release first quarter 2022 financia
4y agoFMTXForma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateBusiness WireClinical stage programs focused on rare hematologic diseases and cancers Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III
4y agoFMTXForma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end
4y agoFMTXForma Therapeutics to Present at 11th Annual SVB Leerink Healthcare ConferenceBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will present at the virtual 11th Annual
4y agoFMTXForma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D CommitteeBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that Arturo Molina, M.D., M.S., F.A.C.P., has be
4y agoFMTXForma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will present at the 40th Annual J.P. Mor
4y agoFMTXForma Therapeutics' Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid LeukemiaBusiness WireFirst Phase 2 combination trial results presented in oral session at 2021 ASH Annual Meeting Olutasidenib with azacitidine well tolerated with a safety profile largely consistent with olutasidenib alone Molecular characteristics of olutasideni
4y agoFMTXForma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell DiseaseBusiness WireUpdated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions Etavopivat was well tolerated with a safety profile consistent with underlying sickle cell disease Clinical data in 15 patients dosed for up to 12 week
4y agoFMTXForma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell DiseaseBusiness WireForma SCD Trend Report: The State of Transition survey reveals 62% of patients found the transition experience "moderately or very challenging" and 73% of physicians state there are a lack of transition guidelines and protocols in their practice or inst
4y agoFMTXForma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient OfficerBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the com
4y agoBOLT FMTX OBSVBolt Biotherapeutics Announces Changes to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of bot
5y agoFMTXForma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness WireSignificant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Soci
5y agoFMTXForma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it will release third quarter 2021 fi
5y agoFMTXForma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual MeetingBusiness WireTwo oral presentations on etavopivat include data from Forma's Phase 1 open label extension trial in sickle cell disease demonstrating a favorable tolerability profile consistent with previously-reported results Additional data supports improvement
5y agoDCPH FMTXMission BioCapital Announces $275 Million Fund VBusiness WireRecord new fund to help biopharma startups achieve pivotal early stage growth Mission BioCapital, a venture capital firm focused on making investments in early-stage life sciences companies that it uniquely supports as they grow, announced it has rai
5y agoFMTXForma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate CancerBusiness WireInitial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients Adaptive trial design intended to efficiently explore safe and efficacious doses of FT-7051 First evaluable
5y agoFMTXForma Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in two upcoming investor conferences: - The Oppenhe
5y agoFMTXForma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness WireSignificant progress achieved with pipeline focused on rare hematologic diseases and cancers Positive Phase 1 results in patients with sickle cell disease (SCD) presented at European Hematology Association (EHA) Virtual Congress supporting etavopivat
5y agoFMTXForma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021. Forma managem
5y agoFMTXForma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology OfficerBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and c
5y agoFMTXForma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association CongressBusiness WireClinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease Initial results from an open-label extension cohort
5y agoFMTXForma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021Business WireOlutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached Durati
5y agoFMTXForma Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in two upcoming investor conferences: The Oppenhe
5y agoFMTXForma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness WireDevelopment pipeline progressing to key upcoming clinical milestones Multiple-ascending dose (MAD) cohorts of FT-4202 Phase 1 trial in sickle cell disease completed; hemoglobin increased ≥ 1 g/dL in approximately 71% of patients and improved hemat
5y agoFMTXForma Therapeutics Holdings Inc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 14, 2021 / Forma Therapeutics Holdings Inc (NASDAQ:FMTX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 8:00 AM Eastern Time. To listen to the event live
5y agoFMTXForma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021Business WireForma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release first quarter 2021 financial results on Friday, May 14, 2021. Forma manage
5y agoFMTXForma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business UpdateBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the fourth quarter and full year ended December 31, 2020. The company also highlighted recent progress and upcoming milestones for its pipeline programs.
5y agoFMTXForma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus StudyBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new data from its ongoing randomized, placebo-controlled, multi-center Phase 1 trial of FT-4202 in patients with sickle cell disease (SCD) that further support the development of this novel investigational ...
5y agoFMTXForma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021Business WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2020 financial results Tuesday, March 30, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on March 30, 2021, ...
5y agoFMTXForma Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in three upcoming investor conferences:
5y agoFMTXForma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)Business WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor (AR) in men with metastatic castration- ...
5y agoFMTXForma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 MilestonesBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a review of corporate highlights from 2020 and outlined anticipated key clinical program milestones for 2021.
5y agoFMTXForma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of DirectorsBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors.
5y agoFMTXForma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of an underwritten public offering of 6,095,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 795,000 shares of c ...
5y agoFMTXForma Therapeutics Announces Pricing of Public OfferingBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock at a public offering price of $45.25 per share. All of the shares of common stock in the offering will be offered by Fo ...
5y agoFMTXForma Therapeutics Launches Proposed Public OfferingBusiness WireWATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it has launched a proposed public offering of 4,600,000 shares of its common stock.
5y agoFMTXForma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)Business WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that clinical proof-of-concept in patients with sickle cell disease (SCD) has been observed in the ongoing randomized, placebo-controlled, multi-center Phase 1 trial of FT-4202. FT-4202 is a novel, investig ...
6y agoFMTXForma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the third quarter ended September 30, 2020. The company also highlighted recent progress and upcoming milestones for its pipeline programs.
6y agoFMTXForma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell DiseaseBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the ...